90 drugs are required to be reported at the national low price, including key monitored varieties

[industry trends of pharmaceutical network] on September 2, Qinghai provincial centralized purchasing network of drugs and medical consumables released the notice on filling in the national low price of some drugs (hereinafter referred to as the notice) According to the notice, 90 drugs, including olacetam capsule, cerebrosine and carnosine injection, sodium phosphocreatine for injection, calf serum deproteinized injection, etc., need to fill in the catalogue of low purchase price varieties in the proposed centralized purchase, including 20 national key monitoring drugs, such as ganglioside, cerebrosine and carnosine, olacetam, sodium phosphocreatine, alprostadil, etc A few days ago, the new version of the medical insurance catalog announced that the 150 varieties transferred out include the 20 national key monitoring drugs for rational use This measure reflects from the side that China's efforts to curb the abuse of complementary drugs have increased again Further forward, on July 1 this year, the national health and Health Commission issued the notice on printing and distributing a batch of national key monitoring and rational drug list (chemical and biological products), which listed 20 kinds of drugs, such as ganglioside, cerebrosine and carnosine, oxiracetam, calf serum deproteinization, alprostadil, complex coenzyme, rat nerve growth factor, etc., into the national key monitoring list According to the industry, these 20 kinds of drugs are chemical and biological products, which can also be understood as clinical auxiliary drugs Due to their wide applicability, they are widely used in hospitals, and many varieties are not cheap According to the database of China Pharmaceutical Industry Information Center, the total sales volume of a batch of national key monitoring drugs for rational use in domestic sample hospitals has reached 14.6 billion yuan Among them, the annual sales of oxiracetam reached 1.49 billion yuan, and the annual sales of deproteinized calf blood extract reached 190 million yuan The average annual sales of 20 drugs is 730 million yuan In addition, among the key monitoring drugs in 2016, the annual sales of monosialotetrahexosylganglioside sodium reached 10 billion yuan, and the total sales of calf blood deproteinized extract reached 7 billion yuan The abuse of these auxiliary drugs will take up a lot of medical insurance funds, so the withdrawal of the medical insurance catalogue is equivalent to "the tiger is locked in the cage", which will have a greater impact on the relevant production enterprises, especially the enterprises focusing on monitoring drugs For example, danshenchuandomazine is a large variety of step pharmaceutical, with an annual sales volume of 4 billion yuan; compound coenzyme for injection of Shuanglu pharmaceutical is the core product of the company, accounting for more than half of the total revenue of Shuanglu pharmaceutical before 2018; RNA is a variety of Jilin Aodong, accounting for 99% of the market share of nuclear glyconucleic acid It can be seen that these key monitoring drugs are facing pressure from policies, price reduction and other aspects, and the future development space is not optimistic, so relevant enterprises need to accelerate the optimization and upgrading of product structure and seek transformation channels According to the schedule, the bidder shall fill in online form through the centralized procurement platform of drugs and medical consumables in Qinghai Province from September 2, 2019 to September 10, 2019 According to the notice, those who do not fill in according to the time, fill in the price as "0" and do not fill in the low purchase price will be deemed to automatically give up participating in this centralized purchase Publicize the price filled in by the enterprise, accept the query - falsely report the low purchase price, cancel the qualification to participate in the centralized purchase, and the enterprise is recorded in the dishonest record The enterprise is not allowed to participate in the centralized purchase of drugs in Qinghai Province within two years In addition, the price of products of the same type, the same dosage form and the different specifications of the same manufacturer shall conform to the principle of differential price comparison.